Literature DB >> 25565460

Mechanical ventilation management during extracorporeal membrane oxygenation for acute respiratory distress syndrome: a retrospective international multicenter study.

Matthieu Schmidt1, Claire Stewart, Michael Bailey, Ania Nieszkowska, Joshua Kelly, Lorna Murphy, David Pilcher, D James Cooper, Carlos Scheinkestel, Vincent Pellegrino, Paul Forrest, Alain Combes, Carol Hodgson.   

Abstract

OBJECTIVE: To describe mechanical ventilation settings in adult patients treated for an acute respiratory distress syndrome with extracorporeal membrane oxygenation and assess the potential impact of mechanical ventilation settings on ICU mortality.
DESIGN: Retrospective observational study.
SETTING: Three international high-volume extracorporeal membrane oxygenation centers. PATIENTS: A total of 168 patients treated with extracorporeal membrane oxygenation for severe acute respiratory distress syndrome from January 2007 to January 2013.
INTERVENTIONS: We analyzed the association between mechanical ventilation settings (i.e. plateau pressure, tidal volume, and positive end-expiratory pressure) on ICU mortality using multivariable logistic regression model and Cox-proportional hazards model. MEASUREMENT AND MAIN
RESULTS: We obtained detailed demographic, clinical, daily mechanical ventilation settings and ICU outcome data. One hundred sixty-eight patients (41 ± 14 years old; PaO2/FIO2 67 ± 19 mm Hg) fulfilled our inclusion criteria. Median duration of extracorporeal membrane oxygenation and ICU stay were 10 days (6-18 d) and 28 days (16-42 d), respectively. Lower positive end-expiratory pressure levels and significantly lower plateau pressures during extracorporeal membrane oxygenation were used in the French center than in both Australian centers (23.9 ± 1.4 vs 27.6 ± 3.7 and 27.8 ± 3.6; p < 0.0001). Overall ICU mortality was 29%. Lower positive end-expiratory pressure levels (until day 7) and lower delivered tidal volume after 3 days on extracorporeal membrane oxygenation were associated with significantly higher mortality (p < 0.05). In multivariate analysis, higher positive end-expiratory pressure levels during the first 3 days of extracorporeal membrane oxygenation support were associated with lower mortality (odds ratio, 0.75; 95% CI, 0.64-0.88; p = 0.0006). Other independent predictors of ICU mortality included time between ICU admission and extracorporeal membrane oxygenation initiation, plateau pressure greater than 30 cm H2O before extracorporeal membrane oxygenation initiation, and lactate level on day 3 of extracorporeal membrane oxygenation support.
CONCLUSIONS: Protective mechanical ventilation strategies were routinely used in high-volume extracorporeal membrane oxygenation centers. However, higher positive end-expiratory pressure levels during the first 3 days on extracorporeal membrane oxygenation support were independently associated with improved survival. Further prospective trials on the optimal mechanical ventilation strategy during extracorporeal membrane oxygenation support are warranted.

Entities:  

Mesh:

Year:  2015        PMID: 25565460     DOI: 10.1097/CCM.0000000000000753

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  49 in total

1.  Severe epistaxis during adult extracorporeal membrane oxygenation: not your average nosebleed.

Authors:  Michael Mazzeffi; Jesse Kiefer; Zachary Kon; Jeffrey Wolf
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

2.  Extracorporeal membrane oxygenation improves survival in a novel 24-hour pig model of severe acute respiratory distress syndrome.

Authors:  Joaquín Araos; Leyla Alegría; Patricio García; Felipe Damiani; Pablo Tapia; Dagoberto Soto; Tatiana Salomon; Felipe Rodriguez; Macarena Amthauer; Benjamín Erranz; Gabriel Castro; Pamela Carreño; Tania Medina; Jaime Retamal; Pablo Cruces; Guillermo Bugedo; Alejandro Bruhn
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

3.  Rescue therapy for refractory ARDS should be offered early: yes.

Authors:  Alain Combes; Marco Ranieri
Journal:  Intensive Care Med       Date:  2015-03-20       Impact factor: 17.440

Review 4.  The ICM research agenda on extracorporeal life support.

Authors:  Alain Combes; Dan Brodie; Yih-Sharng Chen; Eddy Fan; José P S Henriques; Carol Hodgson; Philipp M Lepper; Pascal Leprince; Kunihiko Maekawa; Thomas Muller; Sebastian Nuding; Dagmar M Ouweneel; Antoine Roch; Matthieu Schmidt; Hiroo Takayama; Alain Vuylsteke; Karl Werdan; Laurent Papazian
Journal:  Intensive Care Med       Date:  2017-05-03       Impact factor: 17.440

Review 5.  Mechanical ventilation and respiratory monitoring during extracorporeal membrane oxygenation for respiratory support.

Authors:  Nicolò Patroniti; Giulia Bonatti; Tarek Senussi; Chiara Robba
Journal:  Ann Transl Med       Date:  2018-10

Review 6.  The Role and Impact of Extracorporeal Membrane Oxygenation in Critical Care.

Authors:  Iqbal Ratnani; Divina Tuazon; Asma Zainab; Faisal Uddin
Journal:  Methodist Debakey Cardiovasc J       Date:  2018 Apr-Jun

7.  Focus on veno-venous ECMO in adults with severe ARDS.

Authors:  Laurent Papazian; Margaret Herridge; Alain Combes
Journal:  Intensive Care Med       Date:  2016-06-07       Impact factor: 17.440

Review 8.  Ventilation during extracorporeal support : Why and how.

Authors:  A Pesenti; E Carlesso; T Langer; T Mauri
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-11-28       Impact factor: 0.840

9.  Exogenous surfactant as a bridge to prolonged "total lung rest" in severely injured patient during extracorporeal membrane oxygenation.

Authors:  Peter Sklienka; Jan Maca; Filip Bursa; Jan Neiser; Roman Kula; Marcela Kanova; Tomas Danek; Pavel Sevcik
Journal:  J Artif Organs       Date:  2018-03-27       Impact factor: 1.731

Review 10.  Mechanical ventilation during extracorporeal life support (ECLS): a systematic review.

Authors:  Jonathan D Marhong; Laveena Munshi; Michael Detsky; Teagan Telesnicki; Eddy Fan
Journal:  Intensive Care Med       Date:  2015-03-10       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.